News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Patrys Limited (PAB.AX) Raises A Further $0.9 Million


1/29/2014 9:06:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Melbourne, Australia; 29 January, 2013: Patrys Limited (ASX: PAB; Company) is pleased to confirm that it has raised a further $925,000 before costs through the placement of 18,500,000 shares at an issue price of $0.05 per share as part of the shortfall from the recent Rights Issue.

In accordance with the ASX Listing Rules the Company has 3 months from the date the Rights Issue closed (11 December 2013) to place any shortfall and is continuing to work with Azure Capital Ltd and BBY Ltd on the placement of the remaining 101,434,297 shortfall shares.

The new shares will be entered into the holders’ security holdings on 29 January 2014 with trading of the new shares commencing on 30 January 2014.

Please find an Appendix 3B attached to this announcement.

For further information, please contact:

Patrys Limited:
Roger McPherson
Chief Financial Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:
Rebecca Wilson
Buchan Consulting
P: +61 417 382 391
rwilson@buchanwe.com.au

Patrys Media:
Kellie Hanrick
Buchan Consulting
P: +61 3 9866 4722
khanrick@buchanwe.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that qualify for both internal development and partnering opportunities. More information can be found at www.patrys.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES